I remember participating on a US-based webinar regarding the EU MDR a few years ago. I can't recall the exact numbers, but it was stated that prior to this revision, there were 80 or so NB's. It quickly dropped to 64 the following November, was approximately 56 at the time of the webinar (July 2017) and was expected to decrease to 40 shortly thereafter. So this shouldn't come as a shock to anyone, especially to those creating these new rules.
Not unlike Canada's poorly executed mandatory MDSAP program, this will limit access to technology and potentially patient care. This is a clear example of creating a solution to a problem that didn't exist.